Subscribe
shutterstock_1113551483_sharafmaksumov
sharafmaksumov / Shutterstock.com
11 February 2020Big PharmaRory O'Neill

Clarivate’s ‘drugs to watch’ list signals high prices to come

Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Campaigners ask US govt to force down prices for common drugs
24 March 2022   Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.
Americas
FDA, FTC send message to biologics makers at competition workshop
10 March 2020   US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Generics
Campaigners ask US govt to force down prices for common drugs
24 March 2022   Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.
Americas
FDA, FTC send message to biologics makers at competition workshop
10 March 2020   US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.

More on this story

Generics
Campaigners ask US govt to force down prices for common drugs
24 March 2022   Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.
Americas
FDA, FTC send message to biologics makers at competition workshop
10 March 2020   US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?